Lupin Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Lupin Announces the Approval of Dapagliflozin Tablets in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts less than Nifty Midcap 150 and 2.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin Limited has received approval from the U.S. FDA for its Abbreviated New Drug Application for Dapagliflozin Tablets in 5 mg and 10 mg dosages. The approved product is bioequivalent to Farxiga, which is AstraZeneca's brand-name medication. Dapagliflozin is used for diabetes treatment indications. This approval allows Lupin to launch a generic version of this widely-used medication in the United States market, which is a significant milestone for the company's US portfolio expansion.
This FDA approval is positive for Lupin as it enables the company to enter the US market with a generic version of a popular diabetes drug, potentially creating a new revenue stream and strengthening Lupin's position in the US pharmaceutical market.